Digitisation | April 14, 2026
Imagene AI teams up with Daiichi Sankyo to supercharge cancer drug development
A major push to sharpen the future of cancer treatment is underway
A major push to sharpen the future of cancer treatment is underway
The launch saw the presence of senior clinicians and leadership from the Manipal Hospitals network
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
Panacea Biotec receives LoA from CMSS
The centre offers a full spectrum of FDA-approved services, including physiotherapy, occupational therapy, speech and language therapy, and aqua therapy
The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
Subscribe To Our Newsletter & Stay Updated
